Cyclacel Pharmaceuticals (CYCC) - Quarterly EPS earnings growth

Official company branding of Cyclacel (CYCC)

Cyclacel Pharmaceuticals focuses on developing small molecules for the selective destruction of solid tumors. In the long term, Cyclacel Pharmaceuticals relies on its expertise in CDK proteins and the drug fadraciclib. Quarterly EPS fluctuations on GURU.Markets reflect the current trend, where the indicator value is 99.40. The development strategy is based on the verification of early tests and the attraction of global partners in the general oncotherapy sector.

Cyclacel (CYCC) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 09/12/2025

Analytical breakdowns for Cyclacel Pharmaceuticals

Fundamental company analysis:cyclacel.com, CYCC
Manufactured product of Cyclacel, Inc.

Investors assess the margin of safety through net earnings per share dynamics, which measure the rate of change in real quarterly income relative to the previous period. For Cyclacel Pharmaceuticals (CYCC), which depends on clinical trial outcomes and external financing, the quarterly EPS chart reveals critical volatility in fundamental metrics, confirming the asset's status as a high-speculative risk.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc.|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Corbus Pharma CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months CANF (Can-Fite BioPharma, Ltd.)|APRE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kazia (KZIA)|Year-over-year earnings per share growth for the last twelve months silexion.com|NCNA: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CMRX|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc